Circulating soluble receptor for advanced glycation end-product levels are decreased in patients with calcific aortic valve stenosis

Atherosclerosis

Volumn 210, Issue 2, 2010, Pages 614-618

  Basta, Giuseppina ^a   Corciu, Anca I ^a   Vianello, Annamaria ^b   Del Turco, Serena ^a   Foffa, Ilenia ^c   Navarra, Teresa ^a   Chiappino, Dante ^b   Berti, Sergio ^b   Mazzone, Annamaria ^b  

^a INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^b G Monasterio Foundation   (Italy)

^c SCUOLA SUPERIORE SANT ANNA   (Italy)

Author keywords

Aortic valve stenosis; Atherosclerosis; Soluble receptor for advanced glycation end products

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ANTICOAGULANT AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; C REACTIVE PROTEIN; CALCIUM; INTERLEUKIN 6;

ADULT; AGE DISTRIBUTION; AGED; ANGIOCARDIOGRAPHY; AORTA VALVE REPLACEMENT; AORTA VALVE STENOSIS; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; CORONARY RISK; DIABETES MELLITUS; DISEASE SEVERITY; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTIDETECTOR COMPUTED TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEX DIFFERENCE; TRANSTHORACIC ECHOCARDIOGRAPHY; ULTRASOUND;

AGED; AORTIC VALVE; AORTIC VALVE STENOSIS; C-REACTIVE PROTEIN; CALCINOSIS; CAROTID ARTERIES; CASE-CONTROL STUDIES; CORONARY ANGIOGRAPHY; ECHOCARDIOGRAPHY; FEMALE; GENE EXPRESSION REGULATION; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 77953232228     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.12.029     Document Type: Article

References (31)

1. Basta G., Schmidt A.M., De Caterina R. Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res 2004, 63:582-592.
2. Bucciarelli L.G., Wendt T., Rong L., et al. RAGE is a multiligand receptor of the immunoglobulin superfamily: implications for homeostasis and chronic disease. Cell Mol Life Sci 2002, 59:1117-1128.
3. Wendt T., Harja E., Bucciarelli L., et al. RAGE modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes. Atherosclerosis 2006, 185:70-77.
4. Yonekura H., Yamamoto Y., Sakurai S., et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 2003, 370:1097-1109.
5. Vazzana N., Santilli F., Cuccurullo C., et al. Soluble forms of RAGE in internal medicine. Intern Emerg Med 2009.
6. Geroldi D., Falcone C., Emanuele E. Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target. Curr Med Chem 2006, 13:1971-1978.
7. Ramasamy R., Yan S.F., Schmidt A.M. RAGE: therapeutic target and biomarker of the inflammatory response-the evidence mounts. J Leukoc Biol 2009, 86:505-512.
8. Falcone C., Emanuele E., D'Angelo A., et al. Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol 2005, 25:1032-1037.
9. Koyama H., Shoji T., Yokoyama H., et al. Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 2005, 25:2587-2593.
10. Basta G., Sironi A.M., Lazzerini G., et al. Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein. J Clin Endocrinol Metab 2006, 91:4628-4634.
11. Olsson M., Dalsgaard C.J., Haegerstrand A., et al. Accumulation of T lymphocytes and expression of interleukin-2 receptors in nonrheumatic stenotic aortic valves. J Am Coll Cardiol 1994, 23:1162-1170.
12. Otto C.M., Kuusisto J., Reichenbach D.D., et al. Characterization of the early lesion of 'degenerative' valvular aortic stenosis. Histological and immunohistochemical studies. Circulation 1994, 90:844-853.
13. O'Brien K.D., Reichenbach D.D., Marcovina S.M., et al. Apolipoproteins B, (a), and E accumulate 'degenerative' valvular aortic stenosis. Arterioscler Thromb Vasc Biol 1996, 16:523-532.
14. Rajamannan N.M., Otto C.M. Targeted therapy to prevent progression of calcific aortic stenosis. Circulation 2004, 110:1180-1182.
15. Wallby L., Steffensen T., Broqvist M. Role of inflammation in nonrheumatic, regurgitant heart valve disease. A comparative, descriptive study regarding apolipoproteins and inflammatory cells in nonrheumatic heart valve disease. Cardiovasc Pathol 2007, 16:171-178.
16. Mazzone A., Epistolato M.C., De Caterina R., et al. Neoangiogenesis, T-lymphocyte infiltration, and heat shock protein-60 are biological hallmarks of an immunomediated inflammatory process in end-stage calcified aortic valve stenosis. J Am Coll Cardiol 2004, 43:1670-1676.
17. Galante A., Pietroiusti A., Vellini M., et al. C-reactive protein is increased in patients with degenerative aortic valvular stenosis. J Am Coll Cardiol 2001, 38:1078-1082.
18. Sanchez P.L., Mazzone A. C-reactive protein in degenerative aortic valve stenosis. Cardiovasc Ultrasound 2006, 4:24.
19. Baumgartner H., Hung J., Bermejo J., et al. Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice. J Am Soc Echocardiogr 2009, 22:1-23. quiz 101-102.
20. Tolstrup K., Roldan C.A., Qualls C.R., et al. Aortic valve sclerosis, mitral annular calcium, and aortic root sclerosis as markers of atherosclerosis in men. Am J Cardiol 2002, 89:1030-1034.
21. Stein J.H., Korcarz C.E., Hurst R.T., et al. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine. J Am Soc Echocardiogr 2008, 21:93-111. quiz 189-190.
22. Mark D.B., Nelson C.L., Califf R.M., et al. Continuing evolution of therapy for coronary artery disease. Initial results from the era of coronary angioplasty. Circulation 1994, 89:2015-2025.
23. Agatston A.S., Janowitz W.R., Hildner F.J., et al. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 1990, 15:827-832.
24. Lanati N, Emanuele E, Brondin N, et al. Soluble RAGE-modulating drugs: state-of-the-art and future perspectives for targeting vascular inflammation. Curr Vasc Pharmacol 2010. [Epub ahead of print].
25. Maillard-Lefebvre H., Boulanger E., Daroux M., et al. Soluble receptor for advanced glycation end products: a new biomarker in diagnosis and prognosis of chronic inflammatory diseases. Rheumatology (Oxford) 2009, 48:1190-1196.
26. Santilli F., Vazzana N., Bucciarelli L.G., et al. Soluble forms of RAGE in human diseases: clinical and therapeutical implications. Curr Med Chem 2009, 16:940-952.
27. Parolari A., Loardi C., Mussoni L., et al. Nonrheumatic calcific aortic stenosis: an overview from basic science to pharmacological prevention. Eur J Cardiothorac Surg 2009, 35:493-504.
28. Baidoshvili A., Niessen H.W., Stooker W., et al. N(omega)-(carboxymethyl)lysine depositions in human aortic heart valves: similarities with atherosclerotic blood vessels. Atherosclerosis 2004, 174:287-292.
29. Ren X., Shao H., Wei Q., et al. Advanced glycation end-products enhance calcification in vascular smooth muscle cells. J Int Med Res 2009, 37:847-854.
30. Tanikawa T., Okada Y., Tanikawa R., et al. Advanced glycation end products induce calcification of vascular smooth muscle cells through RAGE/p38 MAPK. J Vasc Res 2009, 46:572-580.
31. Lindsey J.B., de Lemos J.A., Cipollone F., et al. Association between circulating soluble receptor for advanced glycation end products and atherosclerosis: observations from the Dallas Heart Study. Diabetes Care 2009, 32:1218-1220.